Zenith Drugs Ltd (ZENITHDRUG) — shareholding pattern, promoter holding, financials and share price
About Zenith Drugs Ltd (ZENITHDRUG)
Zenith Drugs Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as ZENITHDRUG and on the BSE under scrip code 92356. Its ISIN is INE0QWN01013.
Incorporated in 2000, Zenith Drugs Ltd is in the business of manufacturing and trading of medicines [1]
Zenith Drugs Ltd is a pharmaceutical company specializing in manufacturing affordable, high-quality medicines. Their product range includes ORS powder, liquid orals, ointments, liquid externals, and capsules.
Incorporated in 2000, Zenith has swiftly progressed from a modest manufacturing house to a Schedule M and WHO GMP compliant facility, highlighting their commitment to quality.
Listed peers in Pharmaceuticals: Amwill Health Care Ltd, Curis Lifesciences Ltd, Samrat Pharmachem Ltd, Veerhealth Care Ltd, Bharat Immunological & Biological Corporation Ltd, Sunil Healthcare Ltd.
Valuation & Returns
10 Jul 2026At ₹49.1 a share on 10 Jul 2026, Zenith Drugs Ltd (ZENITHDRUG) was valued at a price-to-earnings ratio of 8.35x against an industry P/E of 36.41x and a price-to-book of 1.25x on a book value of ₹36.31 per share. Solomo computes return on equity of 15.41% and return on capital employed of 18.92% from filed results.
- P/E
- 8.35x
- Industry P/E
- 36.41x
- P/B
- 1.25x
- EPS (TTM)
- ₹5.63
- Book value / share
- ₹36.31
- ROE
- 15.41%
- ROCE
- 18.92%
- ROA
- 6.93%
- Debt / equity
- 0.4x
- Dividend yield
- 0%
- EBITDA margin
- 13.46%
- 52-week range
- ₹33.3 – ₹77
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2024In the year ended Mar 2024, Zenith Drugs Ltd (ZENITHDRUG) reported revenue of ₹131 crore, net profit of ₹10 crore and earnings per share of ₹5.59. That compares with revenue of ₹114 crore and net profit of ₹5 crore in Mar 2023. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹93 crore and net profit ₹2 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|
| Revenue (₹ cr) | 92 | 114 | 131 |
| Net profit (₹ cr) | 3 | 5 | 10 |
| EPS (₹) | - | - | 5.59 |
| Measure | 5Y | 3Y | 1Y |
|---|---|---|---|
| Sales growth | 11.41% | 17.19% | 14.93% |
| Profit growth | 16.06% | 30.62% | 97.75% |
| Stock price CAGR | - | - | -29% |
Ownership Summary
Mar 2026As of Mar 2026, promoters hold 69.98% of Zenith Drugs Ltd (ZENITHDRUG). Market capitalisation was ₹78 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2024.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Mar 2026 | 69.98% | - | - | - | - |
| Sep 2025 | 69.98% | - | - | - | - |
| Mar 2025 | 69.98% | - | - | - | - |
| Sep 2024 | 69.98% | - | - | - | - |
| Mar 2024 | 69.98% | - | - | - | - |